Centessa Pharmaceuticals (NASDAQ:CNTA) Reaches New 12-Month High – Here’s Why

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) shares reached a new 52-week high during mid-day trading on Friday . The company traded as high as $30.00 and last traded at $29.8580, with a volume of 653989 shares trading hands. The stock had previously closed at $29.56.

Wall Street Analysts Forecast Growth

CNTA has been the subject of several research analyst reports. Wall Street Zen raised Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, October 27th. Chardan Capital upgraded Centessa Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, November 19th. Truist Financial set a $30.00 price objective on shares of Centessa Pharmaceuticals in a research note on Wednesday, November 5th. Oppenheimer initiated coverage on shares of Centessa Pharmaceuticals in a research note on Friday, August 29th. They set an “outperform” rating and a $40.00 target price for the company. Finally, Lifesci Capital upgraded shares of Centessa Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, September 3rd. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $35.50.

Centessa Pharmaceuticals Stock Up 1.2%

The company has a current ratio of 10.56, a quick ratio of 10.57 and a debt-to-equity ratio of 0.36. The business’s fifty day moving average price is $24.96 and its 200 day moving average price is $19.03. The company has a market capitalization of $4.02 billion, a P/E ratio of -16.34 and a beta of 1.55.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). As a group, equities research analysts predict that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current fiscal year.

Insider Activity at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, General Counsel Iqbal J. Hussain sold 6,000 shares of the company’s stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $22.41, for a total value of $134,460.00. Following the sale, the general counsel directly owned 105,386 shares in the company, valued at $2,361,700.26. This represents a 5.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Mario Alberto Accardi sold 8,000 shares of the company’s stock in a transaction dated Monday, October 27th. The stock was sold at an average price of $25.00, for a total transaction of $200,000.00. Following the completion of the sale, the insider directly owned 194,394 shares in the company, valued at approximately $4,859,850. The trade was a 3.95% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 179,964 shares of company stock valued at $4,106,481 in the last 90 days. 7.09% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of CNTA. Caitong International Asset Management Co. Ltd increased its holdings in Centessa Pharmaceuticals by 15,209.5% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company’s stock valued at $46,000 after purchasing an additional 3,194 shares in the last quarter. Osterweis Capital Management Inc. bought a new stake in shares of Centessa Pharmaceuticals during the first quarter worth $47,000. Fox Run Management L.L.C. acquired a new stake in shares of Centessa Pharmaceuticals in the first quarter valued at $160,000. Vestal Point Capital LP acquired a new position in Centessa Pharmaceuticals during the 1st quarter worth about $214,000. Finally, Campbell & CO Investment Adviser LLC acquired a new position in Centessa Pharmaceuticals during the 2nd quarter worth about $218,000. 82.01% of the stock is owned by institutional investors and hedge funds.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.